March 23, 2026
India’s pharmaceutical industry has long been celebrated as the “pharmacy of the world,” supplying affordable medicines across continents. Yet, behind this success lies a regulatory framework […]
March 23, 2026
The pharmaceutical world is witnessing a transformative moment with the rise of generic semaglutide. Originally developed as a breakthrough therapy for type-2 diabetes and later recognized […]
March 21, 2026
The Indian pharmaceutical industry is undergoing a transformative shift—one where Environmental, Social, and Governance (ESG) performance is no longer optional but central to long-term capital strategy. […]
February 10, 2026
In a bold move signaling India’s intent to transform its pharmaceutical landscape, the Union Budget 2026-27 has significantly raised the funding for the Department of Pharmaceuticals […]
February 4, 2026
Union Budget 2026, unveiled by Finance Minister Nirmala Sitharaman, put a strong spotlight on healthcare, especially with the ambitious Biopharma SHAKTI scheme — a transformative initiative […]
November 14, 2025
ndia’s regulatory spotlight is shifting. The Drugs Controller General of India (DCGI) has recently launched an aggressive crackdown on small- and medium-sized pharmaceutical manufacturers—particularly those in […]
November 14, 2025
When the Patents Act, 1970’s Section 3(d) came into sharper focus through the Novartis AG v. Union of India ruling and subsequent cases, it marked more […]
November 11, 2025
In a world where body weight often dictates health outcomes, the race to develop effective weight-loss medications has morphed into one of the most fiercely contested […]